药明生物CEO陈智胜受邀出席第44届摩根大通医疗健康大会主会场发表演讲

药明生物01-07

第44届摩根大通医疗健康大会（J.P. Morgan Healthcare Conference 2026）将于当地时间2026年1月12日至15日在美国旧金山举办。药明生物首席执行官陈智胜博士受邀出席盛会，将在JPM主会场上介绍药明生物最新业务进展，并分享行业前沿洞见。作为全球医药健康行业最大的盛会，一年一度的JPM汇聚了老牌制药企业、新兴公司及投资领域的专业人士，也被视为全球医药健康领域发展与...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2601877302?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-07 08:31","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2601877302","market":"hk","top_or_hot":-1,"title":"药明生物CEO陈智胜受邀出席第44届摩根大通医疗健康大会主会场发表演讲","media":"药明生物","content":"<div>\n<p>第44届摩根大通医疗健康大会（J.P. Morgan Healthcare Conference 2026）将于当地时间2026年1月12日至15日在美国旧金山举办。药明生物首席执行官陈智胜博士受邀出席盛会，将在JPM主会场上介绍药明生物最新业务进展，并分享行业前沿洞见。作为全球医药健康行业最大的盛会，一年一度的JPM汇聚了老牌制药企业、新兴公司及投资领域的专业人士，也被视为全球医药健康领域发展与...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107085040a4a538c3&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>药明生物CEO陈智胜受邀出席第44届摩根大通医疗健康大会主会场发表演讲</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n药明生物CEO陈智胜受邀出席第44届摩根大通医疗健康大会主会场发表演讲\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-07 08:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107085040a4a538c3&s=b><strong>药明生物</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>第44届摩根大通医疗健康大会（J.P. Morgan Healthcare Conference 2026）将于当地时间2026年1月12日至15日在美国旧金山举办。药明生物首席执行官陈智胜博士受邀出席盛会，将在JPM主会场上介绍药明生物最新业务进展，并分享行业前沿洞见。作为全球医药健康行业最大的盛会，一年一度的JPM汇聚了老牌制药企业、新兴公司及投资领域的专业人士，也被视为全球医药健康领域发展与...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107085040a4a538c3&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU3063872942.SGD","symbol_name":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107085040a4a538c3&s=b","article_id":"2601877302","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107085040a4a538c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2601877302","pubTimestamp":1767745873,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"第44届摩根大通医疗健康大会将于当地时间2026年1月12日至15日在美国旧金山举办。药明生物首席执行官陈智胜博士受邀出席盛会，将在JPM主会场上介绍药明生物最新业务进展，并分享行业前沿洞见。截至2025年6月底，药明生物帮助客户研发和生产的综合项目高达864个，其中包括24个商业化生产项目。药明生物以可持续发展为长期业务增长的基石。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","BK1589":"北水核心资产","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0823426480.USD":"法巴中国股票经典Dis","BK1610":"ETF&股票定投概念","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0823426308.USD":"法巴中国股票基金","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0051755006.USD":"摩根大通中国A (dist)","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1720050803.USD":"安联全方位中国股票基金","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","02269":"药明生物","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","BK1521":"挪威政府全球养老基金持仓","LU0052750758.USD":"富兰克林中国基金A Acc","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC"},"translate_title":"WuXi Biologics CEO Chen Zhisheng was invited to attend the main venue of the 44th JPMorgan Healthcare Conference and deliver a speech","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1.5},"content_text":"第44届摩根大通医疗健康大会（J.P. Morgan Healthcare Conference 2026）将于当地时间2026年1月12日至15日在美国旧金山举办。药明生物首席执行官陈智胜博士受邀出席盛会，将在JPM主会场上介绍药明生物最新业务进展，并分享行业前沿洞见。作为全球医药健康行业最大的盛会，一年一度的JPM汇聚了老牌制药企业、新兴公司及投资领域的专业人士，也被视为全球医药健康领域发展与投资的风向标。主题演讲KEYNOTE演讲主题A Scaled CRDMO Platform Delivering Sustainable Growth演讲时间1月14日，周三上午 08:15（北美太平洋标准时间）1月15日，周四凌晨 00:15（中国标准时间）参加方式复制下方链接至浏览器或点击文末左下角“阅读原文”注册摩根大通会议参加音频网络直播https://jpmorgan.metameetings.net/events/healthcare26/sessions/317837-wuxi-biologics-inc/webcast?gpu_only=true&kiosk=true网络直播回放及演讲材料将上传至公司官网“投资者关系”专栏，敬请关注！https://www.wuxibiologics.com/investor-events#presentations_webcasts陈智胜博士药明生物首席执行官陈智胜博士现任药明生物首席执行官，在抗体、治疗性蛋白质及疫苗方面拥有丰富工作经验。在他的领导下，药明生物建立了全球领先的生物药发现、开发和生产的一体化平台，赋能超过1000家全球客户，包括小型初创企业和全球TOP 20医药企业。目前，药明生物已支持超过800个生物药项目，包括326个单克隆抗体、168个双/多特异性抗体、225个抗体偶联药物、80个融合蛋白及25个疫苗项目，这也是业界规模最大、复杂度最高的生物药管线之一。公司将单克隆抗体从DNA到新药临床试验申请（IND）的开发时间缩短至9个月，一个自身免疫疾病项目仅在6个月内完成。公司在全球基地应用和推广一次性生产技术及横向拓展策略（scale-out），实现了单批次从4000升到16000升不同规模的生产，2022以来成功率达到98%，在同等规模条件下，成本与不锈钢系统相当。这些里程碑也得益于其世界一流质量体系的支撑，公司以100%的上市许可前检查（PLI）通过率，累计通过包括美国FDA、欧洲药品管理局（EMA）等全球监管机构的44次检查，其中FDA和EMA检查达22次。陈智胜博士拥有美国特拉华大学化学工程博士学位，他曾担任国际制药工程协会（ISPE）国际董事会成员，并成为亚洲首位董事会成员。此前，他曾在礼来、默克及上海赛金生物担任重要管理职位。关于药明生物药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2025年6月底，药明生物帮助客户研发和生产的综合项目高达864个，其中包括24个商业化生产项目。药明生物以可持续发展为长期业务增长的基石。公司持续推动绿色创新技术，为全球合作伙伴提供先进的端到端绿色CRDMO解决方案，同时在ESG方面不断取得卓越成就。秉承创造共享价值的理念，公司携手利益相关方构建可持续发展生态，通过负责任运营模式推动社会价值与生态效益双提升，实现全价值链的协同赋能。更多信息，请访问：www.wuxibiologics.com注：本信息不构成药明生物的信息披露或投资建议请点击右下角【爱心】，并将公众号设为【星标】，第一时间接收药明生物最新动态","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601877302","isCrawlerRequest":true}